World-class R&D
Tetrabody Technology

Tetrabody Technology

Tetrabody Technology is a proprietary “TETRABODY” technology platform developed by Akesobio Global, which helps Akesobio overcome three recurrent CMC challenges in the development and manufacture of bi-specific antibodies. It delivers therapeutic efficacy beyond blockade of PD-1 pathway alone. Building on the validation of PD-1 as a critical immune checkpoint and leveraging our proprietary PD-1 antibody which exhibits activity superior to that of marketed counterparts, Akesobio has adopted a PD-1-based bi-specific pipeline strategy. With TETRABODY, Akesobio has developed and will continue to develop multiple PD-1 based bi-specific antibody drug candidates that cover diverse mechanisms of immune-suppression, as illustrated below. There are also potential opportunities for bi-specific candidates in combination therapy with target therapy or chemotherapy.

Ivonescimab (AK112) was developed using the Tetrabody Technology Platform